Findings

What do systematic reviews say?

5 questions · 10 findings · 2 reviews · Emergency and Critical Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 10%Moderate 4 · 40%High 3 · 30%

Intervention not reported

All‐cause mortality · people suffering from high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · people suffering from high altitude illness

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating acute high altitude illness 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo or no intervention

28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

5 findings from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High

Show 2 more findings

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1.02 [0.84, 1.24]
3 studies · 683 participants
High
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.82 [0.56, 1.19]
2 studies · 262 participants
Moderate

IVIg vs placebo or no intervention

All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).

2 findings from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
5 studies · 3667 participants
Moderate
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 1.01 [0.93, 1.09]
3 studies · 3561 participants
High

IVIg vs placebo or no intervention

All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock

Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).

1 finding from 1 review

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock 2013 · Cochrane Headline outcomes only
RR 0.57 [0.31, 1.04]
3 studies · 164 participants
Low